Skip to content

Effectiveness of Caulophyllum in Primary Dysmenorrhea among Adolescent Girls

THE EFFICIENCY OF CAULOPHYLUM IN TREATING PRIMARY DYSMENORRHEA IN ADOLESCENT GIRLS: A CLINICAL STUDY - Nil

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/05/110701
Enrollment
60
Registered
2026-05-20
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N859- Noninflammatory disorder of uterus, unspecified Health Condition 2: N859- Noninflammatory disorder of uterus, unspecified

Interventions

Intervention1: Caulophyllum Treatment Group: Participants diagnosed with primary dysmenorrhea will receive individualized homoeopathic medicine Caulophyllum in suitable potency and dosage according to

Sponsors

Dr Hetaxi H Chhatraliya
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Age range: Specific age range(e.g., 13 -18 years) Disease or condition: Diagnosis of a specific disease or condition (e.g., Primary dysmenorrhea) Symptoms: Presence of specific symptoms (e.g., Menstrual pain) Health status: Specific health status (e.g., healthy) Demographic characteristics: Specific demographic characteristics (e.g., adolescent girls)

Exclusion criteria

Exclusion criteria: 1) Underlying medical conditions: Conditions that may confound results or increase risk (e.g., secondary dysmenorrhea) 2) Medications: Certain medications that may interact with study treatments or affect outcomes. 3) Pregnancy or lactation: Pregnancy or breastfeeding may affect study outcomes or pose risks. 4) Allergies or sensitivities: Allergies to study medications or materials 5) Non- compliance: Participants unlikely to adhere to study protocols.

Design outcomes

Primary

MeasureTime frame
Reduction in menstrual pain intensity measured by Visual Analogue Scale (VAS)Timepoint: Baseline and every 15 days up to 3 months

Secondary

MeasureTime frame
Reduction in Pain Intensity Timepoint: Baseline,1 month, 2 months and 3 months;Enhanced quality of lifeTimepoint: Baseline and 3 months;Identification of effectiveness of RemediesTimepoint: Baseline and 3 months;Validation of HomoeopathyTimepoint: Baseline and 3 months;Percentage of patient improved /cured /not improvedTimepoint: At 3 months (end of treatment);Overall clinical improvement in symptoms (reducion in pain intensity, Enhanced quality of life)Timepoint: Every 15 days follow up upto 3 months

Countries

India

Contacts

Public ContactDR BRAHMADEO MISHRA

Shree Swaminarayan Homoeopathy College Kalol

drbrmsu2023@swaminarayanuniversity.ac.in9324342414

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 11, 2026